Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882349 | 0.87 | L3MBTL1 (0.36) | L3MBTL1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1883431 | 0.85 | UTS2R (0.36) | L3MBTL1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1883470 | 0.85 | L3MBTL1 (0.35) | L3MBTL1MEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL1883535 | 0.81 | GAA (0.38) | MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL638107 | 0.79 | L3MBTL1 (0.38) | L3MBTL1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1881190 | 0.77 | UTS2R (0.38) | L3MBTL1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1884364 | 0.76 | ACHE (0.35) | — | |
| SCHEMBL1881409 | 0.76 | LPAR2 (0.41) | — | |
| SCHEMBL1883590 | 0.76 | UTS2R (0.37) | L3MBTL1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1886098 | 0.76 | UTS2R (0.37) | L3MBTL1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | L3MBTL1 2410/4885MEN1 3461/4885KMT2A 1917/4885 |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | L3MBTL1 2410/4885MEN1 3461/4885KMT2A 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.